Financing (Tables)

3 Months Ended

Apr. 02, 2021

Debt Disclosure [Abstract]

Components Of Debt

The components of the Company’s debt were as follows ($ in millions):

	April 2, 2021		December 31, 2020
Euro-denominated commercial paper (€500 million)	$	588	$	611
Zero-coupon LYONs due 2021	—		24
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”)	—		290
Floating rate senior unsecured notes due 2022 (€250 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”)	294		305
2.05% senior notes due 2022 (the “2022 Biopharma Notes”)	698		698
0.5% senior unsecured bonds due 2023 (CHF 540 million aggregate principal amount) (the “2023 CHF Bonds”)	574		611
1.7% senior unsecured notes due 2024 (€900 million aggregate principal amount) (the “2024 Euronotes”)	1,054		1,096
2.2% senior unsecured notes due 2024 (the “2024 Biopharma Notes”)	697		697
2.5% senior unsecured notes due 2025 (€800 million aggregate principal amount) (the “2025 Euronotes”)	938		975
3.35% senior unsecured notes due 2025 (the “2025 U.S. Notes”)	498		498
0.2% senior unsecured notes due 2026 (€1.3 billion aggregate principal amount) (the “2026 Biopharma Euronotes”)	1,462		1,520
2.1% senior unsecured notes due 2026 (€800 million aggregate principal amount) (the “2026 Euronotes”)	937		975
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”)	278		297
1.2% senior unsecured notes due 2027 (€600 million aggregate principal amount) (the “2027 Euronotes”)	702		729
0.45% senior unsecured notes due 2028 (€1.3 billion aggregate principal amount) (the “2028 Biopharma Euronotes”)	1,460		1,518
1.125% senior unsecured bonds due 2028 (CHF 210 million aggregate principal amount) (the “2028 CHF Bonds”)	226		241
2.6% senior unsecured notes due 2029 (the “2029 Biopharma Notes”)	795		795
2.5% senior unsecured notes due 2030 (€800 million aggregate principal amount) (the “2030 Euronotes”)	941		978
0.75% senior unsecured notes due 2031 (€1.8 billion aggregate principal amount) (the “2031 Biopharma Euronotes”)	2,046		2,127
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”)	479		514
1.35% senior unsecured notes due 2039 (€1.3 billion aggregate principal amount) (the “2039 Biopharma Euronotes”)	1,453		1,511
3.25% senior unsecured notes due 2029 (the “2039 Biopharma Notes”)	889		889
4.375% senior unsecured notes due 2045 (the “2045 U.S. Notes”)	499		499
1.8% senior unsecured notes due 2049 (€750 million aggregate principal amount) (the “2049 Biopharma Euronotes”)	872		907
3.4% senior unsecured notes due 2049 (the “2049 Biopharma Notes”)	889		889
2.6% senior unsecured notes due 2050 (the “2050 U.S. Notes”)	979		979
Other	29		31
Total debt	20,277		21,204
Less: currently payable	10		11
Long-term debt	$	20,267	$	21,193